The Interlaken Leadership Awards support original research in the field of neuroimmunology. Investigators whose proposals are approved by the review committee will receive monetary grants and/or drug supply. The size of the individual grants is not predetermined, in order to accommodate a wide variety of investigator needs. However small innovative trials and pilot studies may be favoured over large confirmatory trials.
Letters of Intent for the 2017 Interlaken Leadership Awards will be accepted from December 19 through Feb 19, 2018.
Full applications will be accepted through April 30, 2018 by invitation only.
Background
Immunoglobulin therapy has a wide range of indications, from the treatment of immunodeficiencies to the control of autoimmune and inflammatory diseases. The number of potential applications for immunoglobulin therapy continues to expand, and recent research has highlighted several promising novel uses.
To demonstrate its continued commitment to innovative immunoglobulin research, CSL Behring has created the Interlaken Leadership Awards.
Mission statement
The Interlaken Leadership Awards program was created to meet the following objectives:
- To identify new clinical applications for immunoglobulin therapy in the neurology field
- To further investigate the efficacy, mechanisms of action, and treatment optimization of polyvalent immunoglobulins
Program focus
The current focus of the Interlaken Leadership Awards program is to advance medical research and knowledge about the potential role of immunoglobulin therapy in the treatment of neurological disorders.
Past recipients (2013–2017)
2017
- Maarten Titulaer (Netherlands): Intravenous Ig (IVIG) treatment for autoimmune epilepsy (AE) with neuronal antibodies.
- Jean-Philippe Camdessanché (France): Identification, validation, and characterization of novel autoantigens in chronic inflammatory demyelinating polyneuropathy (CIDP).
2016
- Anneke van der Kooi (Netherlands): Early intravenous immunoglobulin (IVIg) treatment in newly diagnosed idiopathic inflammatory myopathies (myositis): a proof of principle study.
- Lisa Christopher-Stine (USA): Low Dose Intravenous and Subcutaneous IG for the Maintenance Treatment of Statin-induced Anti-HMGCR-associated Myopathy: A Prospective Pilot Study.
2014
- Bart Jacobs (Netherlands): Immunoglobulin treatment for patients with mild Guillain-Barré syndrome: an international prospective observational study.
2013
- Andrew J Pollard (UK): Intravenous immunoglobulin in the management of encephalitis in children.
- Min-Suk Yoon (Germany): Effects of intrathecal application of human immunoglobulins (Igs) on rat EAN Model.
About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself.